Horizon Pharma Plc (HZNP) Should Benefit From M&A - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Horizon Pharma (HZNP) Primary Care Sustainable, Rare Disease Solid - PiperJaffray
May 9, 2016 1:02 PM EDTPiper Jaffray analyst, David Amsellem, cut his PT on Horizon Pharma (NASDAQ: HZNP) to $34 from $44 on a lower PE, 13x down from 17x. The lower PE incorporates the greater discount placed on specialty pharma companies of late. The firm maintained its Overweight... More
Horizon Pharma (HZNP) Tops Q1 EPS by 4c
May 9, 2016 7:10 AM EDTHorizon Pharma (NASDAQ: HZNP) reported Q1 EPS of $0.34, $0.04 better than the analyst estimate of $0.30. Revenue for the quarter came in at $204.7 million versus the consensus estimate of $197.73 million.
The Company confirms its full-year and second-quarter net sales and adjusted EBITDA... More
